Manage New Warnings About Clarithromycin and Cardiovascular Risk

April 2018

You'll hear about an increased risk of CV events or death with clarithromycin.

A new FDA warning about this focuses on patients with coronary artery disease (CAD).

Macrolide antibiotics...clarithromycin, erythromycin, and azithromycin...already have warnings about QT prolongation and torsades.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Diabetes Don't Think of A1C Goals as "One-Size-Fits-All"
Vaccines Resolve Common Questions About Shingrix Administration
Cardiology Manage New Warnings About Clarithromycin and Cardiovascular Risk
Infectious Diseases Lean Toward Oral Vancomycin for Initial Treatment of C. diff Diarrhea
Fentanyl Patches Follow Safeguards When Prescribing Fentanyl Patches
Rheumatoid Arthritis Consider Using Subcutaneous Methotrexate More for Rheumatoid Arthritis
Cannabinoids Know How the Rx Cannabinoids Compare
Men s Health Consider if Meds or Supplements May Be Contributing to Male Infertility
Asthma Close the Gap in Asthma Care in Kids
Aspirin Be Prepared With the Latest Answers About Aspirin
Insulin Watch for New "Follow-On" Mealtime Insulin Admelog (Lispro)